A similar profile in DN1 B cells was observed in PASC participants, with DEGs related to increased activation (e.g., CD69 and FCER2) and anti-viral immunity (e.g., CD9 and TRIM5) being upregulated in PASC participants. This evidence concerns the gene FCER2 and long COVID-19.